Lenvatinib superior to sorafenib in patients with unresectable hepatocellular carcinoma
| CONTEXT: Results from a poster presentation at the World Congress on Gastrointestinal Cancer showed lenvatinib was superior to sorafenib as a first line treatment for patients with unresectable hepatocellular carcinoma (HCC). This open-label Phase 3 study run in a real-world setting, looked at 92 patients from Italy and Japan and showed progression-free survival was 7 months for lenvatinib compared to just 4.5 months with Sorafenib. READ TIME: 8 min 1. “Lenvatinib Shown to Be Superior to Sorafenib in Frontline HCC in Real-World Study.” 2. “A propensity score matching analysis presented in a poster during the 2021 World Congress on Gastrointestinal Cancer demonstrated that lenvatinib (Lenvima) was superior to sorafenib (Nexavar) as a first-line treatment for patients with unresectable hepatocellular carcinoma (HCC). ” 3. “Further, the analysis of patients in a real-world setting suggested a number of factors that had possible predictive value for response to lenvatinib. ” 4. “Lenvatinib was suggested to be noninferior to sorafenib as a frontline treatment for patients with unresectable HCC in the open-label phase 3 REFLECT noninferiority trial (NCT01761266). ”  Source URL: https://www.targetedonc.com/view/lenvatinib-shown-to-be-superior-to-sorafenib-in-frontline-hcc-in-real-world-study |